Skip to main content

Advertisement

SpringerLink
Log in

Ductal carcinoma in situ (DCIS)—precision medicine for de-escalation

  • Radiation Oncology (W Woodward, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Purpose of review

Most women undergoing breast conservation surgery (BCS) for ductal carcinoma in situ (DCIS) receive breast radiotherapy (RT) to reduce the incidence of ipsilateral recurrent DCIS and development of invasive disease. This review seeks to appraise the potential for de-escalation of RT based on clinical, biomarker, and/or molecular testing.

Recent findings

Clinical prognostic factors have highlighted young age, tumor (DCIS) size, multifocality, DCIS grade, palpability, and immunohistochemical biomarkers (ER negative, HER2 positive) as prognostic factors. However, molecular markers including the Oncotype DCIS molecular assay alongside clinical factors and most recently the DCISionRT tool incorporating several biomarkers with clinical prognostic factors each appear to have the potential to guide clinical decision-making for the omission of RT. Refinements of these de-escalation tools are continuing. Conversely, markers to demonstrate which patients most need RT, which will then be effective to prevent further disease, are currently lacking.

Summary

Selection of patients undergoing BCS for DCIS who might be suitable for de-escalation (omission) of RT has improved beyond use of a few clinical features to be guided by biomarker and molecular testing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial [see comments]. Lancet. 1999;353(9169):1993–2000.

    Article  CAS  Google Scholar 

  2. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12(1):21–9.

    Article  CAS  Google Scholar 

  3. Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, et al. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. Eur J Cancer. 2018;101:210–9.

    Article  Google Scholar 

  4. (EBCTCG) EBCTCG, Correa C, Mc Gale P, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010:162–77.

    Article  Google Scholar 

  5. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441–52.

    Article  CAS  Google Scholar 

  6. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. [see comments.]. Lancet. 2000;355(9203):528–33.

    Article  CAS  Google Scholar 

  7. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102.

    Article  Google Scholar 

  8. Warnberg F, Garmo H, Emdin S, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol. 2014;32(32):3613–8.

    Article  Google Scholar 

  9. Clements K, Dodwell D, Lawrence G, Ball G, Francis A, Pinder S, et al. Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ. Eur J Surg Oncol. 2015;41(10):1406–10.

    Article  CAS  Google Scholar 

  10. Rakovitch E, Nofech-Mozes S, Hanna W, Sutradhar R, Gu S, Fong C, et al. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy. Breast. 2018;37:181–6.

    Article  Google Scholar 

  11. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88.

    Article  Google Scholar 

  12. Withrow DR, Morton LM, Curtis RE, Schonfeld SJ, Berrington de Gonzalez A. Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers. Breast Cancer Res Treat. 2017;166(1):299–306.

    Article  Google Scholar 

  13. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.

    Article  CAS  Google Scholar 

  14. Harrison BT, Hwang ES, Partridge AH, Thompson AM, Schnitt SJ. Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. Mod Pathol. 2019;32(9):1257–62.

    Article  Google Scholar 

  15. Pinder SE, Duggan C, Ellis IO, et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer. 2010;103(1):94–100.

    Article  CAS  Google Scholar 

  16. Dano H, Altinay S, Arnould L, Bletard N, Colpaert C, Dedeurwaerdere F, et al. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Mod Pathol. 2020;33(3):354–66.

    Article  CAS  Google Scholar 

  17. Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol. 2015;33(33):3938–44.

    Article  Google Scholar 

  18. McCormick B RTOG 9804: A prospective randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). J Clin Oncol. 2012;30(suppl).

  19. McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709–15.

    Article  CAS  Google Scholar 

  20. Rakovitch E, Nofech-Mozes S, Narod S, et al. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat. 2013;138(2):581–90.

    Article  Google Scholar 

  21. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer, version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2018;16(3):310–20.

    Article  Google Scholar 

  22. Worni M, Akushevich I, Greenup R, et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst. 2015;107(12):djv263.

    Article  Google Scholar 

  23. Rakovitch E, Pignol JP, Hanna W, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat. 2007;101(2):335–47.

    Article  Google Scholar 

  24. Sagara Y, Freedman RA, Wong SM, Aydogan F, Nguyen A, Barry WT, et al. Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013. Breast Cancer Res Treat. 2017;166(2):583–92.

    Article  Google Scholar 

  25. Breast Cancer Ductal Carcinoma in Situ. NCCN guidelines for patients. 2020. NCCN.org/patients.

  26. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. JNCI J Natl Cancer Institute. 2010;102(9):627–37.

    Article  CAS  Google Scholar 

  27. Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012;106(6):1160–5.

    Article  CAS  Google Scholar 

  28. Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, et al. Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ-a nested case-control study. Clin Cancer Res. 2018;24(15):3593–601.

    Article  CAS  Google Scholar 

  29. Ladha FK, Lu FY, Tang X, Wistuba I, Sen S, Thompson, A. SOX11 is a potential prognostic marker of high-risk breast ductal carcinoma in situ. Cancer Res. 2019;79(4 Supp).

  30. Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, et al. Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer. JAMA Oncol. 2020;6:505–11.

    Article  Google Scholar 

  31. Sjostrom M, Chang SL, Fishbane N, et al. Clinicogenomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer. J Clin Oncol. 2019;37(35):3340–9.

    Article  Google Scholar 

  32. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10.

    Article  CAS  Google Scholar 

  33. Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152(2):389–98.

    Article  Google Scholar 

  34. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J Natl Cancer Inst. 2017;109(4):djw256.

    Article  Google Scholar 

  35. Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, et al. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat. 2018;169(2):359–69.

    Article  CAS  Google Scholar 

  36. Paszat L, Sutradhar R, Zhou L, Nofech-Mozes S, Rakovitch E. Including the ductal carcinoma-in-situ (DCIS) score in the development of a multivariable prediction model for recurrence after excision of DCIS. Clin Breast Cancer. 2019;19(1):35–46.

    Article  Google Scholar 

  37. Raldow AC, Sher D, Chen AB, Recht A, Punglia RS. Cost effectiveness of the Oncotype DX DCIS Score for guiding treatment of patients with ductal carcinoma in situ. J Clin Oncol. 2016;34:3963–8.

    Article  Google Scholar 

  38. Bremer T, Whitworth P, Patel R, et al. A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk. Clin Cancer Res. 2018;24:5895–901.

    Article  Google Scholar 

  39. Alvarado M, Carter DL, Guenther JM, Hagans J, Lei RY, Leonard CE, et al. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: a prospective clinical utility assessment of the 12-gene DCIS score result. J Surg Oncol. 2015;111(8):935–40.

    Article  Google Scholar 

  40. Manders JB, Kuerer HM, Smith BD, et al. Clinical utility of the 12-Gene DCIS Score Assay: impact on radiotherapy recommendations for patients with ductal carcinoma in situ. Ann Surg Oncol. 2017;24(3):660–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, M4N 3 M5, Canada

    E Rakovitch

  2. Department of Surgery, Dan L Duncan Comprehensive Cancer Center, 7200 Cambridge Street, Houston, TX, 77030, USA

    E Bonefas & AM Thompson

  3. Department of Laboratory Medicine and Molecular Diagnostics, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, M4N 3 M5, Canada

    S Nofech-Mozes

Authors
  1. E Rakovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Bonefas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Nofech-Mozes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. AM Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to AM Thompson.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Radiation Oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rakovitch, E., Bonefas, E., Nofech-Mozes, S. et al. Ductal carcinoma in situ (DCIS)—precision medicine for de-escalation. Curr Breast Cancer Rep 13, 96–102 (2021). https://doi.org/10.1007/s12609-021-00407-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-021-00407-1

Keywords

Search

Navigation